sage-10k_20181231.htm
Sage Therapeutics and Biogen pursue FDA approval for zuranolone
Schematic model for the initial cellular target sites of rapid-acting... | Download Scientific Diagram
Sage Therapeutics' Deal With Biogen Should Revive It (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics Looks to File NDA for Postpartum Depression Treatment Later This Year | BioSpace
Rx Product News: April 2023
Breakthrough Therapy, PRIME and Sakigake: A Comparison Between Neuroscience and Oncology in Obtaining Preferred Regulatory Status - Elena Tomaselli Muensterman, Yijia Luo, Jonathon M. Parker, 2019
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders | Business Wire
Rx Product News: April 2023
SY Investing on X: "$SAGE (-62% PM) announced pivotal Ph 3 MOUNTAIN results of SAGE-217 in MDD. Study didn't meet primary endpoint. #Fail SAGE-217 showed mean reduction of 12.6 in HAM-D total
sage-10k_20191231.htm
Biogen signs deal with Sage to develop depression, tremor therapies
Sage Therapeutics Gets FDA Breakthrough Therapy Designation for Major Depressive Disorder Drug - Equities News
Bipolar Depression: How do we treat it?
Zuranolone, a breakthrough postpartum depression treatment, was just approved by the FDA. The fast-acting pill can improve symptoms in 3 days
Biogen and Sage Therapeutics in Global Collaboration – ISPE Boston
Sage advice: psychiatric drug development is tough | Evaluate
Sage Therapeutics Updates Pipeline to Focus on Treatment-Resistant Depression | BioSpace
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration-CliniExpert
Sage Therapeutics' SAGE-217 fails in late-stage depression trial
Sage Therapeutics stock rockets 73% on hopes for breakthrough depression drug - MarketWatch
Small Clinical Trials Lead To Big Results
Sage And Axsome Face Off In Depression (NASDAQ:AXSM) | Seeking Alpha
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
Proper Résumés - Résumés that stand out and breakthrough applicant tracking systems. | Facebook
Sage Therapeutics surges 70% after depression drug breakthrough
